255 related articles for article (PubMed ID: 7502553)
1. [Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group].
Domschke W; Dettmer A; Fenner T; Gregor M; Hesse P; Holtmann G; van Husen N; Miederer SE; Schentke KU; Schütz E
Z Gastroenterol; 1995 Oct; 33(10):598-601. PubMed ID: 7502553
[No Abstract] [Full Text] [Related]
2. Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Labenz J; Stolte M; Peitz U; Tillenburg B; Köhl H; Becker T; Börsch G
Z Gastroenterol; 1995 Oct; 33(10):590-3. PubMed ID: 7502551
[TBL] [Abstract][Full Text] [Related]
3. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Laine L; Estrada R; Trujillo M; Emami S
Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
[TBL] [Abstract][Full Text] [Related]
4. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
[TBL] [Abstract][Full Text] [Related]
5. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Park KN; Hahm JS; Kim HJ
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
[TBL] [Abstract][Full Text] [Related]
7. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
[TBL] [Abstract][Full Text] [Related]
8. Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Calvet X; García N; Campo R; Brullet E; Comet R; Navarro M
Am J Gastroenterol; 1998 Jun; 93(6):932-4. PubMed ID: 9647022
[TBL] [Abstract][Full Text] [Related]
9. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Bago J; Halle ZB; Strinić D; Kućisec N; Jandrić D; Bevanda M; Tomić M; Bilić A
Wien Klin Wochenschr; 2002 Jun; 114(12):448-53. PubMed ID: 12422579
[TBL] [Abstract][Full Text] [Related]
10. Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled trial.
Kaviani MJ; Malekzadeh R; Vahedi H; Sotoudeh M; Kamalian N; Amini M; Massarrat S
Eur J Gastroenterol Hepatol; 2001 Aug; 13(8):915-9. PubMed ID: 11507355
[TBL] [Abstract][Full Text] [Related]
11. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
Lerang F; Moum B; Haug JB; Tolås P; Breder O; Aubert E; Høie O; Søberg T; Flaaten B; Farup P; Berge T
Am J Gastroenterol; 1997 Feb; 92(2):248-53. PubMed ID: 9040200
[TBL] [Abstract][Full Text] [Related]
12. Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Fennerty MB
Am J Gastroenterol; 1998 Jan; 93(1):2-3. PubMed ID: 9448162
[No Abstract] [Full Text] [Related]
13. [Omeprazole + clarithromycin + metronidazole--a new standard for eradication of Helicobacter pylori].
Schepp W
Z Gastroenterol; 1995 Oct; 33(10):621-3. PubMed ID: 7502558
[No Abstract] [Full Text] [Related]
14. Triple therapy and Helicobacter pylori.
Davis S
Aust Fam Physician; 1996 Jan; 25(1):53, 56-9. PubMed ID: 8607776
[TBL] [Abstract][Full Text] [Related]
15. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amoxicillin.
Chang CS; Yang CY; Wong FN; Chen GH; Lien HC; Yeh HZ; Poon SK
Hepatogastroenterology; 1999; 46(28):2713-7. PubMed ID: 10522070
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole/amoxicillin versus ranitidine/triple therapy for duodenal ulcer: when is the "same" the same?
Maniatis AG; Brazer SR
Am J Gastroenterol; 1994 Jun; 89(6):947-8. PubMed ID: 8198114
[No Abstract] [Full Text] [Related]
17. [Anti-Helicobacter pylori therapy. Who should be treated, how, how long?].
Lux G
Fortschr Med; 1996 Aug; 114(22-23):273-5. PubMed ID: 8974961
[No Abstract] [Full Text] [Related]
18. Bismuth + metronidazole + tetracycline. Why risk adding bismuth?
Prescrire Int; 2013 Apr; 22(137):89-92. PubMed ID: 23662315
[TBL] [Abstract][Full Text] [Related]
19. Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use?
de Boer WA; Kuipers EJ; Kusters JG
Dig Liver Dis; 2004 May; 36(5):311-4. PubMed ID: 15191198
[No Abstract] [Full Text] [Related]
20. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Graham DY; Belson G; Abudayyeh S; Osato MS; Dore MP; El-Zimaity HM
Dig Liver Dis; 2004 Jun; 36(6):384-7. PubMed ID: 15248377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
